Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
  • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
  • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/14—Antitussive agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• This invention relates to a drug combination, its composition and its use in therapy, particularly in the therapy of cough.
• Cough is a protective reflex. Persistent cough can be distressing. Over- the-counter remedies are available but their effectiveness is doubtful.
• W098/42322 discloses the use of theobromine for the treatment of cough, to be given orally.
• the invention is based at least in part on data showing a synergistic antitussive effect for theobromine combined with the decongestant pseudoephedrine, in a citric acid-induced cough model.
• the data show that when theobromine is combined with pseudoephedrine, the effect is surprisingly potent and greater than the sum of the individual drugs, revealing that the combination has a substantially improved effect. This is particularly surprising given that it is doubtful that pseudoephedrine has an antitussive effect at all.
• an agent comprises theobromine and a decongestant, as a combined preparation for simultaneous, sequential or separate use in therapy.
• a pharmaceutical composition comprises theobromine and a decongestant.
• Figure 1 shows the effect of theobromine, and of a combination of theobromine and pseudoephedrine, on citric acid-induced cough in guinea-pig.
• the term "decongestant” is a defined class of drugs, which is well known to the skilled person.
• the decongestant is a a-adrenergic receptor agonist.
• Any suitable form of the decongestant agent may be chosen. These include salts, prodrugs and active metabolites.
• the treatment of cough means any therapy that reduces the number and/or the severity of cough. Preferably, it means a reduction in the number of coughs, i.e. a direct antitussive effect that reduces the body's urge to cough. Therefore, according to a preferred embodiment of the invention, an agent comprises theobromine and a decongestant, for use as an antitussive pharmaceutical composition.
• An agent of the invention is useful as an antitussive in the control of cough. Preferably, it is used in the control of nonproductive cough.
• the decongestant may be used in an amount that is already known for its use, although combination according to this invention means that a reduced dose may be effective.
• the dose of the decongestant that is administered with the theobromine will of course depend on the usual factors, including its potency, but is preferably at least 0.1 , e.g. at least 5, and may be up to 50 mg/kg/day.
• the decongestant is dosed in a range of 0.1 to 30 mg/kg/day.
• any suitable form of theobromine can be chosen. These include salts, prodrugs and active metabolites.
• Theobromine may also be in the form of cocoa or chocolate.
• Suitable dose ranges for theobromine are known in the art and will depend on the usual factors (age etc); although the synergistic effect of the combination means that the effective dose may be reduced.
• a combination according to the invention may be provided in a single formulation or in separate formulations, for combined, simultaneous or sequential administration.
• This decongestant is preferably chosen from the following drugs: ephedrine, levmetamfetamine, naphazoline, oxymetazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, synephrine and tetrahydrozoline. More preferably, the decongestant is pseudoephedrine.
• the compounds of the invention may be administered by any available route, such as via the oral, inhaled, intranasal, sublingual, intravenous, rectal and vaginal routes.
• the compounds of the invention are preferably as combinations to be administered orally, for example as tables, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
• Preferred pharmaceutical compositions of the invention are tablets and capsules. Liquid dispersions for oral administration may be syrups, emulsions and suspensions. More preferably, the pharmaceutical composition of the combination is a pressed tablet or capsule with conventional excipients, examples of which are given below.
• compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
• Tablets contain the combined active ingredients in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
• excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example starch gelatin, acacia, microcrystalline cellulose or polyvinyl pyrrolidone; and lubricating agents, for example magnesium stearate, stearic acid or talc.
• the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
• a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
• Aqueous suspensions contain the combined active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
• excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long-chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids, for example polyoxyethylene sorbitan monooleate.
• suspending agents for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum
• the aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p- hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
• preservatives for example ethyl or n-propyl p- hydroxybenzoate
• colouring agents for example ethyl or n-propyl p- hydroxybenzoate
• flavouring agents such as sucrose or saccharin.
• sweetening agents such as sucrose or saccharin.
• Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, polyoxyethylene hydrogenated castor oil, fatty acids such as oleic acid, or in a mineral oil such as liquid paraffin or in other surfactants or detergents.
• the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
• Sweetening agents, such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
• Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the combined active ingredients in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable sweetening, flavouring and colouring agents may also be present.
• the combined pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
• the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin, or mixtures of these.
• Suitable emulsifying agents may be naturally occurring gums, for example gum acacia or gum tragacanth, naturally occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
• the emulsions may also contain sweetening and flavouring agents.
• Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavouring and colouring agents.
• sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
• Such formulations may also contain a demulcent, a preservative, flavouring and colouring agents.
• Suspensions and emulsions may contain a carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
• a carrier for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
• compositions according to the invention may be produced using conventional formulation techniques.
• spray-drying may be used to produce micro particles comprising the active agent dispersed or suspended within a material that provides the controlled release properties.
• milling for example jet milling
• the process of milling may also be used to formulate the therapeutic composition. This applies particularly to particles intended for administration by inhalation.
• manufacture of fine particles by milling can be achieved using conventional techniques.
• milling is used herein to refer to any mechanical process which applies sufficient force to the particles of active material to break or grind the particles down into fine particles.
• Various milling devices and conditions are suitable for use in the production of the compositions of the invention.
• Suitable homogenisers include the EmulsiFlex high pressure homogeniser, the Niro Soavi high pressure homogeniser and the Microfluidics Microfluidiser.
• the milling process can be used to provide the microparticles with mass median aerodynamic diameters as specified above. If hygroscopic, the active agent may be milled with a hydrophobic material, as stated above.
• the microparticles produced by the milling step can then be formulated with an additional excipient.
• an additional excipient This may be achieved by a spray- drying process, e.g. co-spray-drying.
• the particles are suspended in a solvent and co-spray-dried with a solution or suspension of the additional excipient.
• Preferred additional excipients include polysaccharides. Additional pharmaceutically effective excipients may also be used.
• compositions of the combination intended for inhaled, topical, intranasal, sublingual, intravenous, rectal and vaginal use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
• Therapy according to the invention may be conducted in generally known manner, depending on various factors, such as the sex, age or condition of the patient, and the existence or otherwise of one or more concomitant therapies.
• the patient population may be important.
• the present invention is based at least in part on the following study.
• Guinea pigs were dosed via oral gavage (dose volume 2 mL/kg) with theobromine dosed 2 hours prior to citric acid exposure. Pseudoephedrine was dosed 30 min prior to citric acid exposure and vehicle control animals were dosed both at 2 hours and 30 minutes prior to citric acid exposure.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Emergency Medicine (AREA)
• Pulmonology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (28)

Applications Claiming Priority (2)

Related Parent Applications (3)

Related Child Applications (2)

Publications (1)

Family

ID=41667045

Family Applications (1)

Country Status (19)

Cited By (5)

Citations (2)

Family Cites Families (9)

• 2009
  • 2009-12-14 GB GBGB0921805.8A patent/GB0921805D0/en not_active Ceased
• 2010
  • 2010-12-14 SG SG10201408377QA patent/SG10201408377QA/en unknown
  • 2010-12-14 CN CN2010800570306A patent/CN102740843A/zh active Pending
  • 2010-12-14 UA UAA201208706A patent/UA105944C2/uk unknown
  • 2010-12-14 AU AU2010332494A patent/AU2010332494B2/en not_active Ceased
  • 2010-12-14 CA CA2784214A patent/CA2784214C/en not_active Expired - Fee Related
  • 2010-12-14 PH PH1/2012/501203A patent/PH12012501203A1/en unknown
  • 2010-12-14 SG SG2012043642A patent/SG181686A1/en unknown
  • 2010-12-14 EP EP10795446A patent/EP2512464A1/en not_active Ceased
  • 2010-12-14 BR BR112012014161A patent/BR112012014161A2/pt not_active IP Right Cessation
  • 2010-12-14 JP JP2012543902A patent/JP2013513651A/ja active Pending
  • 2010-12-14 RU RU2012129839/15A patent/RU2564904C2/ru not_active IP Right Cessation
  • 2010-12-14 PE PE2012000813A patent/PE20121537A1/es not_active Application Discontinuation
  • 2010-12-14 CN CN201610214436.XA patent/CN105816462A/zh active Pending
  • 2010-12-14 WO PCT/GB2010/052085 patent/WO2011073646A1/en not_active Ceased
  • 2010-12-14 NZ NZ600243A patent/NZ600243A/xx not_active IP Right Cessation
  • 2010-12-14 MX MX2012006625A patent/MX343222B/es active IP Right Grant
• 2012
  • 2012-06-12 ZA ZA2012/04293A patent/ZA201204293B/en unknown
  • 2012-06-12 EC ECSP12012132 patent/ECSP12012132A/es unknown
  • 2012-06-12 CO CO12098537A patent/CO6541630A2/es unknown
  • 2012-06-13 IL IL220383A patent/IL220383A/en not_active IP Right Cessation
• 2015
  • 2015-09-28 JP JP2015189231A patent/JP2016040279A/ja active Pending

Patent Citations (2)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events